The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study
While Dara-based treatment did not significantly reduce SRE incidence in the overall cohort, it may provide protective benefits against SREs in specific subgroups, particularly among patients without hypercalcemia. Our finding warrants further investigation into the bone-protective effects of Dara in MM.
Authors
- Xiaolei Wei
- X. Li
- Juan Du (ORCID: https://orcid.org/0000-0003-4701-3573)
- Jing Zhou (ORCID: https://orcid.org/0000-0003-3913-8341)
- Zeyu Xiao
- Nianhui Yang
- Hui Zeng
- Hua Wang
- Xiangran Cai
- Yizhen Li
Institutions
- Sun Yat-sen University (CN)
- Integrated Chinese Medicine (China) (HK)
- TCM-Intigrated Cancer Center of Southern Medical University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Jinan University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1186/s12885-025-15250-1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangdong Provincial People's Hospital